Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Crisil - Panacea Biotec Ltd - Independent Equity Research Report

Posted On: 2011-12-14 22:00:23

Panacea Biotec Ltd (Panacea) has so far witnessed strong business momentum in both combination vaccines and formulations. While demand continues to gain traction, Panacea's growth will likely hit a roadblock as WHO (World Health Organisation) has de-listed its combination vaccines, including the high-margin EasyFive, from the pre-qualified list of vaccines. We have lowered our FY12 estimates to account for the loss in business. However, we maintain our fundamental grade of 3/5 as we believe that the problem is likely to be a short term one and the long-term business prospects look optimistic. Growth momentum in combination vaccines stalled in the near term.

Combination vaccines had been witnessing strong traction in demand, apparent from EasyFive's ~220% y-o-y revenue growth in FY11. WHO has recently delisted the product because of quality management issues. Consequently, we expect growth to get stalled as UNICEF is the largest customer. However, management is expecting to fix the issue in 3-4 months. We expect the supplies to resume by Q1FY13 and remain optimistic on the long-term growth prospects of combination vaccines.

Expect gradual de-growth in polio vaccine sales

Polio vaccine sales declined by ~17% y-o-y in FY11 largely due to: 1) decline in procurement by UNICEF because of increase in polio eradication globally, and 2) Indian government now procuring vaccines on need basis only. However, we view limited near-term risk to demand for polio vaccines given the significant number of cases still recorded globally. Going ahead, we expect sales to de-grow, but on a more gradual curve.

New products and geographic expansion to benefit formulations

Formulation sales grew ~24% y-o-y in FY11, largely driven by strong traction in its existing products and entries into new markets. Exports grew by ~110% driven by strong demand for Tacrolimus and Cyclosporine in Latin America. Going ahead, we believe that catalysts such as expected approval in regulated markets and launch of new products will continue to crank the growth engine.

Revenue growth and profitability curve to cave-in in FY12

We expect FY12 revenue to decline ~25% y-o-y to ~Rs 8,650 mn and EBITDA margin to contract by 1,440 bps to ~8% on loss of EasyFive sales to UNICEF and higher raw material costs driven by unfavourable forex movement. We expect revenue and margins to improve to ~Rs 11,934 mn and 19.0% in FY13.

Valuations – the current price has 'upside'

Based on our new estimates, we arrive at a fair value of Rs 100 per share. We propose a valuation grade of 4/5, indicating that the market price has upside from the current levels.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Bandhan: How difficult it is to operate as a bank? - Religare Capital Market
Views on Impact of Rupee Depreciation on IT & Pharmaceuticals - Angel Broking
Views on Aurobindo Pharma receive USFDA Approval for Omeprazole & Ibandraonate Sodium - Angel Broking
Views on Lupin gets USFDA nod for Fenofibrate Tablets - Angel Broking
Views on Sun Pharma announce US FDA approval for Ximino™ - Angel Broking
Oil India - Q1: Subsidy burden impacts PAT - AXIS Capital
Tube Investments: Muted Q1; gradual recovery ahead - AXIS Capital
Astral Polytechnik: Q1 muted; gradual recovery ahead - AXIS Capital
Views on BEML Limited 1QFY2016 Results - Angel Broking
Views on Indag Rubber 1QFY2016 Results - Angel Broking
Views on KNR Constructions Limited 1QFY2016 Results - Angel Broking
Views on Amara Raja Batteries Ltd (ARBL) 1QFY2016 Results - Angel Broking
Views on MBL Infrastructure Ltd 1QFY2016 Results - Angel Broking
Views on on Coal India 1QFY2016 Results: Angel Broking
July CPI inflation eases, production up: DBS Group Research
Views on Cadila Healthcare 1QFY2016 Results - Angel Broking
Views on India Cement 1QFY2016 Results - Angel Broking
Views on IDBI Bank 1QFY2016 Results - Angel Broking
Views on Ashok Leyland Ltd 1QFY2016 Results - Angel Broking
Views on JK Lakshmi Cements 1QFY16 Results - Angel Broking
Views on Sun Pharmaceuticals 1QFY2016 Results - Angel Broking
Views on Tata steel 1QFY2016 Results - Angel Broking
Views on Apollo Tyres Ltd 1QFY2016 Results - Angel Broking
Views on State Bank of India 1QFY2016 Results - Angel Broking
Views on Minda Industries Ltd 1QFY2016 Results - Angel Broking
Views on Power Grid Corp 1QFY2016 Results - Angel Broking
Views on Garware Wall Ropes 1QFY2016 Results - Angel Broking
Views on Radico Khaitan 1QFY2016 Results - Angel Broking
Views on IL&FS Transportation Network 1QFY2016 Results - Angel Broking
Views on Mangalam Cement 1QFY2016 Results: Angel Broking
Views on PNC Infratech 1QFY2016 Results: Angel Broking
Views on Tata Motors 1QFY2016 Results: Angel Broking
Views on Mahindra & Mahindra 1QFY2016 Results: Angel Broking
MT Educare 1QFY2016 Results: Angel Broking
Views on Canara Bank 1QFY2016 Results: Angel Broking
Views on Shree Cement 4QFY2015 Results: Angel Broking
Views on Orient Cement 1QFY2016 Results: Angel Broking
Views on Hero Motocorp 1QFY2016 Results: Angel Broking
Views on HCL Technologies 4QFY2015 Results: Angel Broking
Views on Glaxo Pharmaceuticals 1QFY2016 Results: Angel Broking
Views on Alembic 1QFY2016 Results: Angel Broking
Views on ICICI Bank 1QFY2016 Results: Angel Broking
Views on Exide Industries Ltd 1QFY2016 Results: Angel Broking
BUY NRB Bearings: Anand Rathi Research
Views on Dr Reddys Lab 1QFY2016 Results: Angel Broking
Views on LG Balakrishnan & Bros 1QFY2016 Results: Angel Broking
Views on Dena Bank 1QFY2016 Results: Angel Broking
Views on Cipla - Launches the Pulmicort Respules 1mg /ml generic version: Angel Broking
Views on IPCA Labs 1QFY2016 Results: Angel Broking
Views on Indoco Remedies 1QFY2016 Results: Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2014